Coya Therapeutics’ (COYA) “Buy” Rating Reaffirmed at Chardan Capital

Coya Therapeutics (NASDAQ:COYAGet Free Report)‘s stock had its “buy” rating restated by analysts at Chardan Capital in a report released on Wednesday, Benzinga reports. They currently have a $14.00 target price on the stock. Chardan Capital’s target price would indicate a potential upside of 100.57% from the stock’s previous close.

Coya Therapeutics Trading Up 0.3 %

COYA opened at $6.98 on Wednesday. Coya Therapeutics has a 1-year low of $3.21 and a 1-year high of $10.69. The stock’s fifty day simple moving average is $8.45 and its 200 day simple moving average is $7.77. The stock has a market cap of $102.05 million, a PE ratio of -8.21 and a beta of 0.77.

Coya Therapeutics (NASDAQ:COYAGet Free Report) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.35) earnings per share for the quarter. The company had revenue of $0.13 million during the quarter. Equities analysts forecast that Coya Therapeutics will post -1.3 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. AIGH Capital Management LLC grew its holdings in Coya Therapeutics by 92.6% in the 4th quarter. AIGH Capital Management LLC now owns 1,031,977 shares of the company’s stock valued at $7,381,000 after buying an additional 496,183 shares in the last quarter. Vanguard Group Inc. grew its holdings in Coya Therapeutics by 772.3% in the 1st quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock valued at $8,407,000 after buying an additional 750,338 shares in the last quarter. Finally, Greenlight Capital Inc. grew its holdings in Coya Therapeutics by 172.2% in the 4th quarter. Greenlight Capital Inc. now owns 1,274,026 shares of the company’s stock valued at $9,441,000 after buying an additional 805,959 shares in the last quarter. 39.75% of the stock is owned by institutional investors and hedge funds.

Coya Therapeutics Company Profile

(Get Free Report)

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.

Featured Articles

Receive News & Ratings for Coya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.